Co-op CARs for targeting acute myeloid leukemia

Taisuke Kondo; Naomi Taylor

doi:10.1016/j.ccell.2023.09.015

Co-op CARs for targeting acute myeloid leukemia

Cancer Cell. 2023 Nov 13;41(11):1841-1843. doi: 10.1016/j.ccell.2023.09.015. Epub 2023 Oct 12.

Authors

Taisuke Kondo¹, Naomi Taylor²

Affiliations

¹ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: taisuke.kondo@nih.gov.
² Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Université de Montpellier-IGMM, Montpellier, France. Electronic address: taylorn4@mail.nih.gov.

PMID: 37832553
DOI: 10.1016/j.ccell.2023.09.015

Abstract

Chimeric antigen receptor (CAR) T cell therapies are limited by antigen escape and on-target/off-tumor toxicity. In addressing these challenges, Haubner et al. develop an "IF-BETTER" strategy. Their combinatorial chimeric co-stimulatory receptor with an attenuated CAR enhances acute myeloid leukemia (AML) killing while protecting healthy progenitors, highlighting the potential to leverage cooperative CAR designs.

Publication types

Research Support, N.I.H., Intramural
Comment

MeSH terms

Humans
Immunotherapy, Adoptive
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy

Grants and funding

ZIA BC011923/ImNIH/Intramural NIH HHS/United States